Generic - Equivalent drugs use in internal and general medicine patients: Distrust, confusion, lack of certainties or of knowledge? Part 3. Clinical issues

Italian Journal of Medicine

Volumn 8, Issue 2, 2014, Pages 99-109

  Nardi, Roberto ^a   Masina, Marco ^b   Cioni, Giorgio ^c   Leandri, Paolo ^a   Zuccheri, Paola ^a  

^a MAGGIORE HOSPITAL   (Italy)

^b Ospedale di Bentivoglio   (Italy)

^c AUSL Modena   (Italy)

Author keywords

Clinical issues; Generic equivalent drugs; Highly variable drugs; Narrow therapeutic index and critical dose drugs; Special subpopulations; Therapeutic substitution and therapeutic interchange

Indexed keywords

GENERIC DRUG;

ARTICLE; BIOEQUIVALENCE; CONFUSION; CONTROLLED RELEASE FORMULATION; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EPILEPSY; FRAIL ELDERLY; GENERAL PRACTICE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFORMED CONSENT; ITALY; PRESCRIPTION; RISK ASSESSMENT; TRUST;

EID: 84901338146     PISSN: 18779344     EISSN: 18779352     Source Type: Journal    
DOI: 10.4081/itjm.2014.400     Document Type: Article

References (59)

1. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003;25:2875-90. (Pubitemid 37510596)
2. Shaw SL, Hartman AL. The controversy over generic antiepileptic drugs. J Pediatr Pharmacol Ther 2010;15: 81-93.
3. Fukuntoto KH. Generic drug substitution: role and function, legislative reform. Hawaii 16813, report no. 7. Honolulu: Bureau State Capitol; 1990.
4. US Food and Drug Administration. Code of Federal Regulations. Title 21 - Part 320: Bioavailability and bioequivalence requirements. Section 320.24. Types of evidence to measure bioavailability or establish bioequivalence. Silver Spring, MD: FDA; 2003. Available from: http://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=320.24
5. Holmes DR Jr, Becker JA, Granger CB, et al. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. Circulation 2011;124:1290-310.
6. European Medicines Agency-Committee For Medicinal Products For Human Use (EMA-CHMP). Pre-authorisation evaluation of medicines for human use - Guideline on the investigation of bioequivalence. Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1. 24 July. London: EMA; 2008. Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003011.pdf
7. Pope ND. Generic substitution of narrow therapeutic index drugs. Generic Drug Rev 2009;34:12-9.
8. Reiffel JA. Issues in the use of generic antiarrhythmic drugs. Curr Opin Cardiol 2001;16:23-9. (Pubitemid 32060027)
9. Bolton S. Bioequivalence studies for levothyroxine. AAPS J 2005;7:E47-53.
10. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? a review of issues. Seizure 2006;15: 165-76.
11. Gidal BE, Tomson T. Debate: substitution of generic drugs in epilepsy: is there cause for concern? Epilepsia 2008;49:56-62.
12. Hope KA, Havrda DE. Subtherapeutic INR values associated with a switch to generic warfarin. Ann Pharmacother 2001;35:183-7. (Pubitemid 32127127)
13. Milligan PE, Banet GA, Waterman AD, Gatchel SK. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002;36:764-8. (Pubitemid 34517402)
14. Vasquez EM, Min DI. Transplant pharmacists' opinions on generic product selection of critical-dose drugs. Am J Health Syst Pharm 1999;56:2246-7.
15. Blume H, Zhong D, Elze M. Advantages of a steady-state crossover design in assessment of bioequivalence of highly variable drugs: propafenone. Eur J Pharm Sci 1994;2:385-93.
16. Health Canada, Therapeutic Products Directorate (TPD). Discussion paper on "Bioequivalence requirements - highly variable drugs and highly variable drug products: issues and options". Expert Advisory Committee on Bioavailability and Bioequivalence (EAC-BB) Meeting, June 26-27, 2003.
17. Diliberti CE. Why bioequivalence of highly variable drugs is an issue. In: FDA Advisory Committee for Pharmaceutical Sciences and Clinical Pharmacology meeting transcript. US Food and Drug Administration Dockets; Apr 14 2004. Available from: http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4034T2.htm
18. Tothfalusi L, Endrenyi L, Arieta AG. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet 2009;48:725-43.
19. Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther 2005;43:485-98. (Pubitemid 41448423)
20. Tajana A. Bioequivalenza: la nuova linea guida dell'EMEA, 49° Simposio AFI - Giugno 2009. Available from: http://www.afiscientifica.it/all/ TAJANA.pdf
21. Perucca E. Equivalenti nelle sotto-popolazioni fragili: il punto di vista del farmacologo. BIF 2008;3:118-20.
22. Gidal BE. Antiepileptic drug formulation and treatment in the elderly: biopharmaceutical considerations. Int Rev Neurobiol 2007;81:299-311.
23. Peters JR, Hixon DR, Conner DP, et al. Generic drugs - safe, effective and affordable. Dermatol Ther 2009;22: 229-40.
24. Marzo A, Porro E, Barassi A. Generic drugs: myths, facts, and limitations. Ital J Med 2012;6:146-52.
25. Greene JA, Kessleheim AS. Why do the same drugs look different? Pills, trade dress, and public health. N Engl J Med 2011;365:83-9.
26. Emery J, McKenzie A, Bulsara C, Holman D. Controversy over generic substitution. BMJ 2010;341:c3570.
27. Kesselheim AS, Misono AS, Shrank WH, et al. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med 2013;173:202-8.
28. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2006;40:15-20. (Pubitemid 43221468)
29. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003;42:107-21. (Pubitemid 36188552)
30. McGilveray IJ. Bioequivalence studies of drugs prescribed mainly for women. Popul Ther Clin Pharmacol 2011;18:e516-22.
31. US Food and Drug Administration. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products - General considerations. Revision 1, March 2003. Available from: http://www.fda.gov/ downloads/Drugs/.../Guidances/ucm070124.pdf
32. Harrison J. Safety considerations associated with generic interchangeability in transplant medicine. Toronto General Hospital, University Health Network; 21 Sept 2011. Available from: http://www.benefitscanada. com/wp-content/uploads/2011/09/Jennifer- Harrison-Astellas.pdf
33. European Society for Organ Transplantation. Advisory Committee on generic substitution of immunosuppressive drugs; March, 2011.
34. Società Italiana Trapianti d'Organo. Considerazioni sull'uso degli immunosoppressori equivalenti dopo trapianto d'organo solido; II stesura, 2011. Available from: http://www.societaitalianatrapiantidiorgano.com/documenti/ Farmaci-generici-SITO.pdf
35. Helderman JH, Kang N, Legorreta AP, Chen JY. Healthcare costs in renal transplant recipients using branded versus generic ciclosporin. Appl Health Econ Health Policy 2010;8:61-8.
36. van Gelder T; ESOT Advisory Committee on Generic Substitution. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transpl Int 2011;24:1135-41.
37. Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following use of generic vs. brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010;70:605-21.
38. Privitera MD. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr 2008;8: 113-7.
39. American Epileptic Society. Position statement on the substitution of different formulations of antiepileptic drugs for the treatment of epilepsy; November 29, 2007. Available from: http://www.aesnet.org/go/press-room/ consensus-statements/drug-substitution
40. Perucca E, Albani F, Capovilla G, et al. Raccomandazioni del gruppo di studio LICE in merito all'utilizzo di prodotti generici di farmaci antiepilettici. Boll Lega Ital Epil 2007;135:33-9. (Pubitemid 351448209)
41. Privitera M. Generic substitution of antiepileptic drugs: What's a clinician to do? Neurol Clin Pract 2013;3: 161-4.
42. Tschabitscher D, Platzer P, Baumgärtel C, Müllner M. Generic drugs: quality, efficacy, safety and interchangeability. Wien Klin Wochenschr 2008;120:63-9. (Pubitemid 351361639)
43. Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol 2010;70:335-41.
44. Garattini S. Maggiore ricerca per i farmaci generici. Ital J Med 2012;6:145.
45. Zarowitz BJ. The generic imperative. Geriatr Nurs 2008;29:223-6.
46. Gruppo di lavoro CF AVEC (Commissione Farmaco Area Vasta Emilia Romagna Centro). I farmaci a brevetto scaduto. Bologna: Servizio Sanitario Regionale Emilia-Romagna; 2013. Available from: http://www.odmbologna.it/ViewPost/Index/ 2231
47. Green JB, Ross JS, Jackevicius CA, et al. When choosing statin therapy: the case for generics. JAMA Intern Med 2013;173:229-32.
48. Campbell EG, Pham-Kanter G, Vogeli C, Iezzoni LI. Physician acquiescence to patient demands for brandname drugs: results of a national survey of physicians. JAMA Intern Med 2013;173:237-9.
49. Lewek P, Kardas P. Generic drugs: the benefits and risks of making the switch. Family Practice 2010;59:634-40.
50. Chu C, Rudant E, Bonvalet M, et al. Generic drug prescriptions following hospital discharge: a prospective study in France. J Intern Med 2011;22:e45-9.
51. Federman AD, Halm EA, Siu AL. Use of generic cardiovascular medications by elderly medicare beneficiaries receiving generalist or cardiologist care. Medical Care 2007;45:109-15.
52. Manolakis PG. Prescription drug pro duct substitution decision support. J Am Pharm Assoc 2007;47:328-38.
53. Milillo G. Il punto di vista di FIMMG. Giorn Ital Farmacoecon Farmacoutil 2013;1:46.
54. Aronson JK. Medication errors resulting from the confusion of drug names. Expert Opin Drug Saf 2004;3: 167-72. (Pubitemid 38765199)
55. Sabatini S, Ferguson RM, Helderman JH, et al. Drug substitution in transplantation: a National Kidney Foundation White Paper. Am J Kidney Dis 1999;33:389-97. (Pubitemid 29072246)
56. Redazione di Dialogo sui Farmaci (a cura di). Farmaci generici: dubbi o pregiudizi? un sondaggio di Dialogo sui Farmaci. Dialogo sui Farmaci 2007;2:75-7. Available from: http://www.dialogosuifarmaci.it/rivista/pdf/CO- 200703-2-1089.pdf
57. Perucca E. Equivalenti nelle sotto-popolazioni fragili: il punto di vista del farmacologo. BIF 2008;3:118-20.
58. Marzo A, Porro E, Barassi A. Generic drugs: myths, facts, and limitations. Ital J Med 2012;6:146-52.
59. Caldwell DJ, Jaubert K, Zagar M, Sherman J. Considerations for generic drug use in the elderly. Pharmacy Times 2007, Jan 1. Available from: http://www.pharmacytimes.com/publications/issue/2007/2007-01/2007-01-6215